PARIS–(BUSINESS WIRE)–Regulatory Information:
Hospitex, the Italian chief within the manufacturing of medical units and a subsidiary of ALIKO SCIENTIFIC (Ikonisys SA) ( Euronext (EPA:) Development Paris: ALIKO), immediately declares that it has secured a public tender for the Azienda Ospedaliera Universitaria “Gaetano Martino” in Messina, Italy.
The contract, valued at €668 thousand over three years, contains an choice to increase it for 2 further years, bringing the whole potential worth to €1.025 million. The tender covers the provision of alcohol for medical and hospital use, a significant element for sustaining excessive requirements of healthcare providers.
Hospitex is accredited as a fiscal warehouse for alcohol by the Italian Customs Company, a distinction that’s among the many most difficult to acquire because of advanced regulatory, logistical, infrastructural, and administrative necessities. This accreditation demonstrates Hospitex’s operational excellence and positions the corporate as a trusted provider able to working in extremely advanced regulated environments.
The corporate’s experience in hydroalcoholic options and pure alcohol manufacturing extends past Italy, as Hospitex serves healthcare establishments throughout Europe, underscoring its capability to ship dependable, high-quality medical alcohol options on a broad scale.
Francesco Trisolini, CEO of Hospitex, acknowledged: “Securing this tender reaffirms our management within the healthcare sector and our potential to navigate the complexities of regulatory and logistical frameworks. Our fiscal warehouse accreditation highlights our operational excellence and demonstrates our readiness to fulfill the wants of each home and worldwide shoppers. We’re proud to associate with the Gaetano Martino College Hospital and stay dedicated to delivering essential provides that help healthcare excellence.”
This achievement reinforces ALIKO SCIENTIFIC’s strategic place within the healthcare and life sciences sectors, supporting its development targets and dedication to innovation.
About ALIKO SCIENTIFIC (Ikonisys SA)
Headquartered in Paris, ALIKO SCIENTIFIC is the dad or mum firm of a world ecosystem of companies devoted to advancing oncology diagnostics. Listed on Euronext Development Paris beneath the ticker ALIKO, the corporate coordinates industrial, monetary and analysis actions by its subsidiaries: Ikonisys Inc. (USA) and Hospitex Worldwide (Italy). ALIKO SCIENTIFIC’s mission is to innovate most cancers analysis by uniting cutting-edge applied sciences, assets, and strategic investments to create a worldwide middle of excellence in oncology.
For extra info, go to: www.alikoscientific.com
About IKONISYS
Ikonisys is a worldwide chief in automated diagnostics, specializing in fluorescence in situ hybridization (FISH) and circulating tumor cell (CTC) detection. Leveraging superior synthetic intelligence (AI) and a totally automated microscopy platform, Ikonisys gives unmatched precision, scalability, and effectivity in most cancers diagnostics and therapy monitoring. Acknowledged as pioneer in automation for uncommon cell detection, Ikonisys is on the forefront of personalised drugs, empowering clinicians to ship focused therapies and enhance affected person outcomes.
For extra info, go to: www.ikonisys.com
About HOSPITEX
Hospitex, based mostly in Florence, Italy, is a worldwide chief in cytology innovation. The corporate conducts in-house analysis, growth, and manufacturing, thus making certain the best requirements of high quality. Hospitex affords the world’s most superior Liquid-Primarily based Cytology (LBC) expertise, able to processing any cytological pattern with unmatched precision. Hospitex is uniquely positioned as the one firm totally ready for seamless digital integration, paving the way in which for a transformative future in cytology diagnostics.
For extra info, go to: www.hospitex.com
Disclaimer
This press launch comprises forward-looking statements concerning the Firm’s prospects and growth. These statements are generally recognized by means of the long run tense, the conditional tense and forward-looking phrases resembling “consider”, “goal to”, “anticipate”, “intend”, “estimate”, “consider”, “ought to”, “may”, “would” or “will” or, the place acceptable, the unfavorable of those phrases or another comparable variants or expressions. This info just isn’t historic information and shouldn’t be construed as a assure that the information and information set forth will happen. This info is predicated on information, assumptions and estimates thought of affordable by the Firm. It’s topic to alter or modification because of uncertainties regarding the financial, monetary, aggressive and regulatory setting. This info comprises information regarding the Firm’s intentions, estimates and targets regarding, particularly, the market, technique, development, outcomes, monetary state of affairs and money movement of the Firm. The forward-looking info contained on this press launch is made solely as of the date of this press launch. The Firm doesn’t undertake to replace any forward-looking info contained on this press launch, besides as required by relevant regulation or regulation. The Firm operates in a aggressive and quickly altering setting and subsequently can not anticipate the entire dangers, uncertainties or different components which will have an effect on its enterprise, their potential influence on its enterprise or the extent to which the materialization of anyone threat or mixture of dangers may trigger outcomes to vary materially from these expressed in any forward-looking info, it being recalled that none of this forward-looking info constitutes a assure of precise outcomes.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20250114677393/en/
Ikonisys
Alessandro Mauri
CFO
buyers@ikonisys.com
NewCap
Louis-Victor Delouvrier/Aurélie Manavarere
Investor Relations
ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 94
NewCap
Nicolas Merigeau
Media Relations
ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 98
Supply: Ikonisys
